|By PR Newswire||
|December 12, 2012 08:01 PM EST||
MIGDAL HAEMEQ, Israel, December 13, 2012 /PRNewswire/ --
A randomized, double-blind, controlled clinical trial on bone strength in term infants fed a high beta-palmitate formula was recently published in the journal Calcified Tissue International. The results of the study indicate significantly higher bone-strength parameters compared to a standard vegetable oil control.
The trial was conducted by Ita Litmanovitz, MD., et al, at Meir Medical Center, Kfar Saba, Israel, and sponsored by Enzymotec. The trial studied the effect of 12 weeks feeding of infant formula with InFat® (Advanced Lipids, a joint venture between AAK and Enzymotec(, high beta-palmitate fat blend, on bone strength parameters. Bone strength results were measured by speed of sound, using quantitative ultrasound (QUS).
The clinical trial included 83 term infants, 58 formula-fed and 25 breast-fed. The formula fed infants were assigned to a study group receiving formula with InFat, or to a control group receiving formula using standard vegetable oil mix. Bone-strength parameters, measured by QUS (Sunlight Premier Software, Omnisense BeamMed, Ltd.), plus anthropometric parameters, were measured at randomization, then at 6 and 12 weeks postnatal age.
"We are very pleased with the study results," says Yael Lifshitz, Ph.D., Director of R&D, Enzymotec Infant Nutrition. "This clearly indicates that InFat benefits bone strength parameters. Bone speed of sound of the newborns fed the formula with InFat was significantly higher than that of newborns fed the control formula, and comparable to that of breast-fed newborns."
"This trial marks an important milestone in our clinical development program, positioning InFat as a premium fat blend for infant formulas," adds Tzafra Cohen, Ph.D., CEO of Advanced Lipids. "It shows Advanced Lipids' commitment to our customers and the infant nutrition market to continued investment in research. We also anticipate finding additional benefits to the use of InFat."
InFat is a clinically-proven fat blend (beta-palmitate structured lipids) for infant formula with a high percentage of palmitic acid in its sn-2 position. This mimics the unique composition of human milk fat, which is highly conserved in all women's breast milk, and thereby enables optimized uptake of calcium and energy as well as easy digestion.
Enzymotec is a research-based biotech company that develops, manufactures and markets innovative lipid-based, bio-functional ingredients and final products. Enzymotec delivers innovative solutions via three divisions. The Enzymotec Infant Nutrition division develops lipid compositions that mimic human milk fat to facilitate healthy infant development.
About Advanced Lipids
Advanced Lipids is a joint venture between AAK and Enzymotec for the sales and marketing of InFat. Advanced Lipids offers InFat as a concentrate form or as any tailored oil blend enriched with beta-palmitate (high sn2). InFat is produced in AAK's state of the art production facilities in Sweden based on proprietary enzymatic technology developed by Enzymotec.
For more information please contact:
- "All It Took Was One E-Mail to Larry," Says Former eBay Research Director As He Moves to Google
- Google Ramps Up Its Mobile Reach: Launches "Mobile Web Search"
- VoIP Update: Yahoo! Buys DialPad
- Ericsson + Napster = World's First "Wireless Digital Music" Brand
- Free Guest Passes for the SOA World Conference & Expo in NYC
- SYS-CON i-Technology Podcast August 30, 2005
- A Flair for Food - Health-Conscious Cooking Is This Chef's Cup Of Tea
- Sony PSP May Feature Porn
- Kapow Helps Seiko UK, Provides SMS Text-Alert Services
- South Korea is World's Largest Phisher